Supriya Lifescience Ltd., founded in 1987 by Satish Wagh, is a prominent Indian pharmaceutical company that focuses on the production of active pharmaceutical ingredients (APIs). Based in Mumbai, the company operates a cutting-edge manufacturing facility in Maharashtra that adheres to global standards, including those set by the USFDA and WHO-GMP.
On December 9, 2024, Supriya Lifescience Ltd. announced that it had achieved two significant milestones aimed at enhancing its international presence. Notably, it has become the first Indian company to obtain approval from Brazil’s health authority, ANVISA, for Esketamine Hydrochloride.
This milestone will enable Supriya Lifescience to broaden its product range in Brazil and the wider Latin American (LATAM) region.
Esketamine hydrochloride is employed in the treatment of mental health conditions and could attract interest in the LATAM market. The firm stated that ANVISA’s endorsement will allow it to deliver advanced, high-quality healthcare solutions in a market where there is a rising demand for innovative and reasonably priced medications.
In another update, the company announced that it has submitted a patent application for an economical manufacturing process for Atorvastatin, a commonly prescribed drug used to manage cholesterol levels and prevent cardiovascular issues.
“This innovative technique enhances the affordability of medications for patients by improving their effectiveness while lowering production expenses,” the company stated.
Satish Wagh, Executive Chairman and Whole Time Director of Supriya Lifescience remarked, “Our dedication to revolutionising pharmaceutical manufacturing while upholding affordability is reflected in our innovation in the synthesis of atorvastatin.”
He continued, “Our global standing has been bolstered by the approval from Brazilian authorities, which enables us to launch advanced treatments such as Esketamine Hydrochloride in key international markets, beginning with Brazil.”
At 2:18 PM, shares of Supriya Lifescience Ltd. were trading at ₹774.30 on the NSE, down 1%. The lowest price traded currently stands at ₹767.00, while the highest price recorded is ₹792.95 per share.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
